Ocugen (OCGN) Cash from Investing Activities (2014 - 2026)
Ocugen's (OCGN) quarterly Cash from Investing Activities came in at -$6000.0 in Q1 2026, up 94.12% YoY from -$3090.9 in Q1 2025, and up 82.86% on a QoQ basis from -$35000.0 in Q4 2025.
Powered by 
Analysis
Ocugen (OCGN) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Cash from Investing Activities data on file, last reported at -$6000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 94.12% year-over-year to -$6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215000.0 (up 81.06% YoY) and the FY2025 annual result came in at -$311000.0, up 90.81% from the prior year.
- Cash from Investing Activities improved to -$6000.0 in Q1 2026, from -$35000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $5.7 million in Q2 2023 to a low of -$15.3 million in Q4 2022.
- A 5-year average of -$1.0 million and a median of -$102000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 7866.15% — and 2023, when it surged 1643.05%.
- Tracing OCGN's Cash from Investing Activities over 5 years: stood at -$15.3 million in 2022, then surged by 82.2% to -$2.7 million in 2023, then jumped by 99.52% to -$13000.0 in 2024, then tumbled by 169.23% to -$35000.0 in 2025, then surged by 82.86% to -$6000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$6000.0 (Q1 2026), -$35000.0 (Q4 2025), and -$86000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | -21,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21,000.00 |
| Mar 31, 2026 | -6,000.00 |
| Dec 31, 2025 | -35,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -88,000.00 |
| Mar 31, 2025 | -102,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | -507,000.00 |
| Jun 30, 2024 | -513,000.00 |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | -2.72 Mn |
| Sep 30, 2023 | -3.37 Mn |
| Jun 30, 2023 | 5.72 Mn |
| Mar 31, 2023 | 3.44 Mn |
| Dec 31, 2022 | -15.30 Mn |
| Sep 30, 2022 | -83,000.00 |
| Jun 30, 2022 | -1.37 Mn |
| Mar 31, 2022 | -223,000.00 |
| Dec 31, 2021 | -192,000.00 |
| Sep 30, 2021 | -350,000.00 |